NEUROTROPE BIOSCIENCE is a biopharmaceutical and diagnostics company principally focused on developing a drug candidate called Bryostatin-1 for the treatment of Alzheimer's Disease. The company recently received FDA approval to initiate a Phase 2 clinical trial. In a variety of in vitro and in vivo models of neurodegeneration, including Alzheimer's Disease, the company's experimental drug prototypes have arrested the ongoing process of neurodegeneration, and in many cases reversed this process leading to the restoration of full nerve cell function.